Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
Identifieur interne : 002941 ( Ncbi/Checkpoint ); précédent : 002940; suivant : 002942Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
Auteurs : Joseph Torresi [Australie] ; Leon G. Heron [Australie] ; Ming Qiao [Australie] ; Joanne Marjason [Australie] ; Laurent Chambonneau [France] ; Alain Bouckenooghe [Singapour] ; Mark Boaz [États-Unis] ; Diane Van Der Vliet [France] ; Derek Wallace [Singapour] ; Yanee Hutagalung [Singapour] ; Michael D. Nissen [Australie] ; Peter C. Richmond [Australie]Source :
- Vaccine [ 1873-2518 ] ; 2015.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Anticorps antiviraux (sang), Anticorps neutralisants (sang), Australie, Dengue (), Femelle, Humains, Injections sous-cutanées, Jeune adulte, Mâle, Placebo (administration et posologie), Vaccins atténués (administration et posologie), Vaccins atténués (effets indésirables), Vaccins atténués (immunologie), Vaccins atténués (normes), Vaccins contre la dengue (administration et posologie), Vaccins contre la dengue (effets indésirables), Vaccins contre la dengue (immunologie), Vaccins contre la dengue (normes), Volontaires sains.
- MESH :
- administration et posologie : Placebo, Vaccins atténués, Vaccins contre la dengue.
- effets indésirables : Vaccins atténués, Vaccins contre la dengue.
- immunologie : Vaccins atténués, Vaccins contre la dengue.
- normes : Vaccins atténués, Vaccins contre la dengue.
- sang : Anticorps antiviraux, Anticorps neutralisants.
- Adolescent, Adulte, Adulte d'âge moyen, Australie, Dengue, Femelle, Humains, Injections sous-cutanées, Jeune adulte, Mâle, Volontaires sains.
- Wicri :
- geographic : Australie.
English descriptors
- KwdEn :
- Adolescent, Adult, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Australia, Dengue (prevention & control), Dengue Vaccines (administration & dosage), Dengue Vaccines (adverse effects), Dengue Vaccines (immunology), Dengue Vaccines (standards), Female, Healthy Volunteers, Humans, Injections, Subcutaneous, Male, Middle Aged, Placebos (administration & dosage), Vaccines, Attenuated (administration & dosage), Vaccines, Attenuated (adverse effects), Vaccines, Attenuated (immunology), Vaccines, Attenuated (standards), Young Adult.
- MESH :
- chemical , administration & dosage : Dengue Vaccines, Placebos, Vaccines, Attenuated.
- chemical , adverse effects : Dengue Vaccines, Vaccines, Attenuated.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- chemical , immunology : Dengue Vaccines, Vaccines, Attenuated.
- chemical , standards : Dengue Vaccines, Vaccines, Attenuated.
- geographic : Australia.
- prevention & control : Dengue.
- Adolescent, Adult, Female, Healthy Volunteers, Humans, Injections, Subcutaneous, Male, Middle Aged, Young Adult.
Abstract
The recombinant yellow fever-17D-dengue virus, live, attenuated, tetravalent dengue vaccine (CYD-TDV) has undergone extensive clinical trials. Here safety and consistency of immunogenicity of phase III manufacturing lots of CYD-TDV were evaluated and compared with a phase II lot and placebo in a dengue-naïve population.
DOI: 10.1016/j.vaccine.2015.08.008
PubMed: 26279339
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002A04
- to stream PubMed, to step Curation: 002934
- to stream PubMed, to step Checkpoint: 002934
- to stream Ncbi, to step Merge: 002941
- to stream Ncbi, to step Curation: 002941
Links to Exploration step
pubmed:26279339Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.</title><author><name sortKey="Torresi, Joseph" sort="Torresi, Joseph" uniqKey="Torresi J" first="Joseph" last="Torresi">Joseph Torresi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Austin Hospital, Heidelberg, Melbourne, VIC, Australia; Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Parkville, Melbourne, VIC, Australia. Electronic address: josepht@unimelb.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Infectious Diseases, Austin Hospital, Heidelberg, Melbourne, VIC, Australia; Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Parkville, Melbourne, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="Heron, Leon G" sort="Heron, Leon G" uniqKey="Heron L" first="Leon G" last="Heron">Leon G. Heron</name><affiliation wicri:level="1"><nlm:affiliation>National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead, Westmead, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead, Westmead, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Qiao, Ming" sort="Qiao, Ming" uniqKey="Qiao M" first="Ming" last="Qiao">Ming Qiao</name><affiliation wicri:level="1"><nlm:affiliation>Royal Adelaide Hospital, SA Pathology, Adelaide, SA, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Royal Adelaide Hospital, SA Pathology, Adelaide, SA</wicri:regionArea><wicri:noRegion>SA</wicri:noRegion></affiliation></author><author><name sortKey="Marjason, Joanne" sort="Marjason, Joanne" uniqKey="Marjason J" first="Joanne" last="Marjason">Joanne Marjason</name><affiliation wicri:level="1"><nlm:affiliation>Q-Pharm Pty Ltd, Herston 4006, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Q-Pharm Pty Ltd, Herston 4006, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Chambonneau, Laurent" sort="Chambonneau, Laurent" uniqKey="Chambonneau L" first="Laurent" last="Chambonneau">Laurent Chambonneau</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Development, Sanofi Pasteur, Marcy l'Etoile, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Development, Sanofi Pasteur, Marcy l'Etoile</wicri:regionArea><wicri:noRegion>Marcy l'Etoile</wicri:noRegion><wicri:noRegion>Marcy l'Etoile</wicri:noRegion></affiliation></author><author><name sortKey="Bouckenooghe, Alain" sort="Bouckenooghe, Alain" uniqKey="Bouckenooghe A" first="Alain" last="Bouckenooghe">Alain Bouckenooghe</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Development, Sanofi Pasteur, Singapore, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Clinical Development, Sanofi Pasteur, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Boaz, Mark" sort="Boaz, Mark" uniqKey="Boaz M" first="Mark" last="Boaz">Mark Boaz</name><affiliation wicri:level="2"><nlm:affiliation>Global Clinical Immunology, Sanofi Pasteur, Swiftwater, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Clinical Immunology, Sanofi Pasteur, Swiftwater, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Van Der Vliet, Diane" sort="Van Der Vliet, Diane" uniqKey="Van Der Vliet D" first="Diane" last="Van Der Vliet">Diane Van Der Vliet</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Development, Sanofi Pasteur, Marcy l'Etoile, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Development, Sanofi Pasteur, Marcy l'Etoile</wicri:regionArea><wicri:noRegion>Marcy l'Etoile</wicri:noRegion><wicri:noRegion>Marcy l'Etoile</wicri:noRegion></affiliation></author><author><name sortKey="Wallace, Derek" sort="Wallace, Derek" uniqKey="Wallace D" first="Derek" last="Wallace">Derek Wallace</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Development, Sanofi Pasteur, Singapore, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Clinical Development, Sanofi Pasteur, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Hutagalung, Yanee" sort="Hutagalung, Yanee" uniqKey="Hutagalung Y" first="Yanee" last="Hutagalung">Yanee Hutagalung</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Development, Sanofi Pasteur, Singapore, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Clinical Development, Sanofi Pasteur, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Nissen, Michael D" sort="Nissen, Michael D" uniqKey="Nissen M" first="Michael D" last="Nissen">Michael D. Nissen</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Trials Centre, Queensland Paediatric Infectious Diseases Laboratory, Queensland Children's Medical Research Institute, Royal Children's Hospital, Herston, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Clinical Trials Centre, Queensland Paediatric Infectious Diseases Laboratory, Queensland Children's Medical Research Institute, Royal Children's Hospital, Herston, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Richmond, Peter C" sort="Richmond, Peter C" uniqKey="Richmond P" first="Peter C" last="Richmond">Peter C. Richmond</name><affiliation wicri:level="1"><nlm:affiliation>University of Western Australia School of Paediatrics and Child Health and Vaccine Trials Group, Telethon Kids Institute, Subiaco, WA, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>University of Western Australia School of Paediatrics and Child Health and Vaccine Trials Group, Telethon Kids Institute, Subiaco, WA</wicri:regionArea><wicri:noRegion>WA</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26279339</idno><idno type="pmid">26279339</idno><idno type="doi">10.1016/j.vaccine.2015.08.008</idno><idno type="wicri:Area/PubMed/Corpus">002A04</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A04</idno><idno type="wicri:Area/PubMed/Curation">002934</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002934</idno><idno type="wicri:Area/PubMed/Checkpoint">002934</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002934</idno><idno type="wicri:Area/Ncbi/Merge">002941</idno><idno type="wicri:Area/Ncbi/Curation">002941</idno><idno type="wicri:Area/Ncbi/Checkpoint">002941</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.</title><author><name sortKey="Torresi, Joseph" sort="Torresi, Joseph" uniqKey="Torresi J" first="Joseph" last="Torresi">Joseph Torresi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Austin Hospital, Heidelberg, Melbourne, VIC, Australia; Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Parkville, Melbourne, VIC, Australia. Electronic address: josepht@unimelb.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Infectious Diseases, Austin Hospital, Heidelberg, Melbourne, VIC, Australia; Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Parkville, Melbourne, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="Heron, Leon G" sort="Heron, Leon G" uniqKey="Heron L" first="Leon G" last="Heron">Leon G. Heron</name><affiliation wicri:level="1"><nlm:affiliation>National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead, Westmead, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead, Westmead, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Qiao, Ming" sort="Qiao, Ming" uniqKey="Qiao M" first="Ming" last="Qiao">Ming Qiao</name><affiliation wicri:level="1"><nlm:affiliation>Royal Adelaide Hospital, SA Pathology, Adelaide, SA, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Royal Adelaide Hospital, SA Pathology, Adelaide, SA</wicri:regionArea><wicri:noRegion>SA</wicri:noRegion></affiliation></author><author><name sortKey="Marjason, Joanne" sort="Marjason, Joanne" uniqKey="Marjason J" first="Joanne" last="Marjason">Joanne Marjason</name><affiliation wicri:level="1"><nlm:affiliation>Q-Pharm Pty Ltd, Herston 4006, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Q-Pharm Pty Ltd, Herston 4006, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Chambonneau, Laurent" sort="Chambonneau, Laurent" uniqKey="Chambonneau L" first="Laurent" last="Chambonneau">Laurent Chambonneau</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Development, Sanofi Pasteur, Marcy l'Etoile, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Development, Sanofi Pasteur, Marcy l'Etoile</wicri:regionArea><wicri:noRegion>Marcy l'Etoile</wicri:noRegion><wicri:noRegion>Marcy l'Etoile</wicri:noRegion></affiliation></author><author><name sortKey="Bouckenooghe, Alain" sort="Bouckenooghe, Alain" uniqKey="Bouckenooghe A" first="Alain" last="Bouckenooghe">Alain Bouckenooghe</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Development, Sanofi Pasteur, Singapore, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Clinical Development, Sanofi Pasteur, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Boaz, Mark" sort="Boaz, Mark" uniqKey="Boaz M" first="Mark" last="Boaz">Mark Boaz</name><affiliation wicri:level="2"><nlm:affiliation>Global Clinical Immunology, Sanofi Pasteur, Swiftwater, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Global Clinical Immunology, Sanofi Pasteur, Swiftwater, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Van Der Vliet, Diane" sort="Van Der Vliet, Diane" uniqKey="Van Der Vliet D" first="Diane" last="Van Der Vliet">Diane Van Der Vliet</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Development, Sanofi Pasteur, Marcy l'Etoile, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Development, Sanofi Pasteur, Marcy l'Etoile</wicri:regionArea><wicri:noRegion>Marcy l'Etoile</wicri:noRegion><wicri:noRegion>Marcy l'Etoile</wicri:noRegion></affiliation></author><author><name sortKey="Wallace, Derek" sort="Wallace, Derek" uniqKey="Wallace D" first="Derek" last="Wallace">Derek Wallace</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Development, Sanofi Pasteur, Singapore, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Clinical Development, Sanofi Pasteur, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Hutagalung, Yanee" sort="Hutagalung, Yanee" uniqKey="Hutagalung Y" first="Yanee" last="Hutagalung">Yanee Hutagalung</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Development, Sanofi Pasteur, Singapore, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Clinical Development, Sanofi Pasteur, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="Nissen, Michael D" sort="Nissen, Michael D" uniqKey="Nissen M" first="Michael D" last="Nissen">Michael D. Nissen</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Trials Centre, Queensland Paediatric Infectious Diseases Laboratory, Queensland Children's Medical Research Institute, Royal Children's Hospital, Herston, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Clinical Trials Centre, Queensland Paediatric Infectious Diseases Laboratory, Queensland Children's Medical Research Institute, Royal Children's Hospital, Herston, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Richmond, Peter C" sort="Richmond, Peter C" uniqKey="Richmond P" first="Peter C" last="Richmond">Peter C. Richmond</name><affiliation wicri:level="1"><nlm:affiliation>University of Western Australia School of Paediatrics and Child Health and Vaccine Trials Group, Telethon Kids Institute, Subiaco, WA, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>University of Western Australia School of Paediatrics and Child Health and Vaccine Trials Group, Telethon Kids Institute, Subiaco, WA</wicri:regionArea><wicri:noRegion>WA</wicri:noRegion></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Antibodies, Neutralizing (blood)</term><term>Antibodies, Viral (blood)</term><term>Australia</term><term>Dengue (prevention & control)</term><term>Dengue Vaccines (administration & dosage)</term><term>Dengue Vaccines (adverse effects)</term><term>Dengue Vaccines (immunology)</term><term>Dengue Vaccines (standards)</term><term>Female</term><term>Healthy Volunteers</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term><term>Placebos (administration & dosage)</term><term>Vaccines, Attenuated (administration & dosage)</term><term>Vaccines, Attenuated (adverse effects)</term><term>Vaccines, Attenuated (immunology)</term><term>Vaccines, Attenuated (standards)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps antiviraux (sang)</term><term>Anticorps neutralisants (sang)</term><term>Australie</term><term>Dengue ()</term><term>Femelle</term><term>Humains</term><term>Injections sous-cutanées</term><term>Jeune adulte</term><term>Mâle</term><term>Placebo (administration et posologie)</term><term>Vaccins atténués (administration et posologie)</term><term>Vaccins atténués (effets indésirables)</term><term>Vaccins atténués (immunologie)</term><term>Vaccins atténués (normes)</term><term>Vaccins contre la dengue (administration et posologie)</term><term>Vaccins contre la dengue (effets indésirables)</term><term>Vaccins contre la dengue (immunologie)</term><term>Vaccins contre la dengue (normes)</term><term>Volontaires sains</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dengue Vaccines</term><term>Placebos</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dengue Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Dengue Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="standards" xml:lang="en"><term>Dengue Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Australia</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Placebo</term><term>Vaccins atténués</term><term>Vaccins contre la dengue</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins atténués</term><term>Vaccins contre la dengue</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins atténués</term><term>Vaccins contre la dengue</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Vaccins atténués</term><term>Vaccins contre la dengue</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dengue</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Female</term><term>Healthy Volunteers</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Australie</term><term>Dengue</term><term>Femelle</term><term>Humains</term><term>Injections sous-cutanées</term><term>Jeune adulte</term><term>Mâle</term><term>Volontaires sains</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Australie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The recombinant yellow fever-17D-dengue virus, live, attenuated, tetravalent dengue vaccine (CYD-TDV) has undergone extensive clinical trials. Here safety and consistency of immunogenicity of phase III manufacturing lots of CYD-TDV were evaluated and compared with a phase II lot and placebo in a dengue-naïve population.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li><li>Singapour</li><li>États-Unis</li></country><region><li>Pennsylvanie</li></region></list><tree><country name="Australie"><noRegion><name sortKey="Torresi, Joseph" sort="Torresi, Joseph" uniqKey="Torresi J" first="Joseph" last="Torresi">Joseph Torresi</name></noRegion><name sortKey="Heron, Leon G" sort="Heron, Leon G" uniqKey="Heron L" first="Leon G" last="Heron">Leon G. Heron</name><name sortKey="Marjason, Joanne" sort="Marjason, Joanne" uniqKey="Marjason J" first="Joanne" last="Marjason">Joanne Marjason</name><name sortKey="Nissen, Michael D" sort="Nissen, Michael D" uniqKey="Nissen M" first="Michael D" last="Nissen">Michael D. Nissen</name><name sortKey="Qiao, Ming" sort="Qiao, Ming" uniqKey="Qiao M" first="Ming" last="Qiao">Ming Qiao</name><name sortKey="Richmond, Peter C" sort="Richmond, Peter C" uniqKey="Richmond P" first="Peter C" last="Richmond">Peter C. Richmond</name></country><country name="France"><noRegion><name sortKey="Chambonneau, Laurent" sort="Chambonneau, Laurent" uniqKey="Chambonneau L" first="Laurent" last="Chambonneau">Laurent Chambonneau</name></noRegion><name sortKey="Van Der Vliet, Diane" sort="Van Der Vliet, Diane" uniqKey="Van Der Vliet D" first="Diane" last="Van Der Vliet">Diane Van Der Vliet</name></country><country name="Singapour"><noRegion><name sortKey="Bouckenooghe, Alain" sort="Bouckenooghe, Alain" uniqKey="Bouckenooghe A" first="Alain" last="Bouckenooghe">Alain Bouckenooghe</name></noRegion><name sortKey="Hutagalung, Yanee" sort="Hutagalung, Yanee" uniqKey="Hutagalung Y" first="Yanee" last="Hutagalung">Yanee Hutagalung</name><name sortKey="Wallace, Derek" sort="Wallace, Derek" uniqKey="Wallace D" first="Derek" last="Wallace">Derek Wallace</name></country><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Boaz, Mark" sort="Boaz, Mark" uniqKey="Boaz M" first="Mark" last="Boaz">Mark Boaz</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002941 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 002941 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:26279339
|texte= Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:26279339" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |